Table 2.
Predicted per year benefits of Wolbachia programmes in four sites. Only eligible areas (at least 1000 people per km2) receive treatment. All costs are in 2018 US dollars and are not discounted. Figures in brackets represent 95% uncertainty intervals
| Committed area | Scale-up scenario | |||
|---|---|---|---|---|
| Yogyakarta City | Remaining Yogyakarta SAR | Jakarta | Bali | |
| Baseline cases per year (area wide) | 14,488 (2955–47,858) | 93,604 (21,527–249,843) | 444,528 (97,542–1,189,217) | 117,840 (27,862–324,114) |
| Post Wolbachia cases per year (area wide) | 722 (0–30,140) | 36,674 (6805–180,567) | 127,712 (0–749,850) | 62,033 (9810–237,984) |
| Area-wide percent reduction (%) | 94.4 (36.5–100) | 59.1 (25.6–69.6) | 65.7 (36.7–100) | 52.4 (24.2–66.9) |
| Percent reduction within treated areas | 94.4 (36.5–100) | 87.2 (37.2–100) | 65.7 (36.7–100) | 82.8 (37.3–100) |
| Averted medical costs per year (millions USD) | 0.46 (0.14–1.19) | 2.16 (0.67–4.70) | 12.91 (4.49–25.08) | 2.58 (0.82–5.11) |
| Averted societal costs per year (millions USD) | 0.52 (0.21–0.98) | 2.36 (1.05–4.28) | 14.17 (6.09–24.27) | 2.77 (1.23–4.74) |